How Has the Gastroparesis Drugs Market Evolved Historically and What is its Current Size?
The gastroparesis drugs market has seen considerable growth due to a variety of factors.
• The gastroparesis drugs market has grown strongly in recent years. It will rise from $5.39 billion in 2024 to $5.73 billion in 2025, at a compound annual growth rate (CAGR) of 6.3%.
The historical growth is linked to side effects of current treatments, research into gastrointestinal motility, clinical needs, patient advocacy, and regulatory support.
What is the Forecasted Market Size and CAGR for the Gastroparesis Drugs Market?
The gastroparesis drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The gastroparesis drugs market is forecasted to reach $7.2 billion by 2029, growing at a CAGR of 5.9%.
Growth will be driven by the increasing prevalence of diabetes, an aging population, rising awareness and diagnosis rates, greater healthcare spending, and increased funding from government and private sectors. Trends include advancements in gastroenterology, better diagnostic techniques, and more research funding and collaborative efforts.
What Key Factors and Trends Are Driving The Growth Gastroparesis Drugs Market?
The growing prevalence of diabetes is expected to drive the gastroparesis drugs market. Diabetes, which leads to high blood sugar and affects the body’s use of insulin, is rising due to poor diets, sedentary lifestyles, and aging populations. Gastroparesis, a condition often affecting people with diabetes, causes delayed stomach emptying and requires medication to manage symptoms like nausea and vomiting. According to the UK’s Office for Health Improvement & Disparities, more individuals with type 1 and type 2 diabetes received recommended care between 2022 and 2023, reflecting the rising need for gastroparesis treatment.
What Are The Market Segments In The Gastroparesis Drugs Market?
The gastroparesis drugs market covered in this report is segmented –
1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce
Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants
Pre-Book The Gastroparesis Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Gastroparesis Drugs Market?
In the gastroparesis drugs market, companies are introducing new medications, such as the Gimoti (metoclopramide) nasal spray, to treat gastroparesis symptoms. For example, in April 2022, Evoke Pharma announced that the FDA granted new drug exclusivity for Gimoti, providing three years of market exclusivity. The nasal spray bypasses the GI tract and offers direct absorption into the bloodstream, improving stomach motility.
Who Are the Key Players In The Gastroparesis Drugs Market?
Major companies operating in the gastroparesis drugs market are:
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi SA.
• AstraZeneca plc
• Abbott Laboratories
• GSK plc
• Takeda Pharmaceutical Inc.
• Teva Pharmaceutical Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Evoke Pharma Inc.
• Cadila Pharmaceuticals
• Cipla Ltd.
• Neurogastrx Inc.
• Ipca Laboratories Ltd.
• ANI Pharmaceuticals Inc.
• Salix Pharmaceuticals Inc.
• Vanda Pharmaceuticals Inc.
• Theravance Biopharma Inc.
• Rhythm Pharmaceuticals Inc.
• Processa Pharmaceuticals Inc.
• Aclipse Therapeutics LLC
• ETX Pharma Inc.
What Are The Regional Insights Into The Gastroparesis Drugs Market?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
